SpectraScience (SpectraScience) Change In Receivables : $0.00 Mil (TTM As of Sep. 2017)

View and export this data going back to . Start your Free Trial

What is SpectraScience Change In Receivables?

SpectraScience's change in receivables for the quarter that ended in Sep. 2017 was $0.00 Mil. It means SpectraScience's Accounts Receivable stayed the same from Jun. 2017 to Sep. 2017 .

SpectraScience's change in receivables for the fiscal year that ended in Dec. 2016 was $0.01 Mil. It means SpectraScience's Accounts Receivable declined by $0.01 Mil from Dec. 2015 to Dec. 2016 .

SpectraScience's Accounts Receivable for the quarter that ended in Sep. 2017 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. SpectraScience's liquidation value for the three months ended in Sep. 2017 was $-14.17 Mil.

SpectraScience Change In Receivables Historical Data

The historical data trend for SpectraScience's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SpectraScience Change In Receivables Chart

SpectraScience Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Change In Receivables

Get a 7-Day Free Trial

0.03

0.02

0.06

-0.01

0.01

SpectraScience Quarterly Data
	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

SpectraScience Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

SpectraScience (GREY:SCIE) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

SpectraScience's Days Sales Outstanding for the quarter that ended in Sep. 2017 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, SpectraScience's accounts receivable are only considered to be worth 75% of book value:

SpectraScience's liquidation value for the quarter that ended in Sep. 2017 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.028	-	14.246	+	0.75 * 0	+	0.5 * 0.097
=	-14.17

SpectraScience Change In Receivables Related Terms

Thank you for viewing the detailed overview of SpectraScience's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

SpectraScience (SpectraScience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SpectraScience Inc (GREY:SCIE) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

11568-11 Sorrento Valley Road, San Diego, CA, USA, 92121

Website

http://www.spectrascience.com

SpectraScience Inc is a US based company focused on developing the WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The firm has developed a technology platform to determine if the tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT operates by using cool, safe UV laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin treatment during the same procedure. The group sells its product in the United States and Europe, of which majority of the sales revenue is derived from the United States.

Executives

Lowell Giffhorn	officer: CFO	10875 KEMAH LANE, SAN DIEGO CA 92131
John Pappajohn	director	1660 WALT WHITMAN ROAD, SUITE 105, MELVILLE NY 11747
Euclidsr Partners, L.p.	10 percent owner	45 ROCKEFELLER PLAZA, SUITE 3240, NEW YORK NY 10111
Euclidsr Associates, L.p.	10 percent owner	45 ROCKEFELLER PLAZA, SUITE 3240, NEW YORK NY 10111
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105

SpectraScience (SpectraScience) Headlines

No Headlines